Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.91
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.91
November 12, 2018 4:05 PM EST
Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET
BERKELEY HEIGHTS, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the third quarter 2018. The Company's net loss applicable to common shareholders for the three months ended September 30, 2018 was $2.1 million. As of September 30, 2018, cash and cash equivalents totaled $19.0 million.
We continue to execute on our strategy to rapidly develop CYC065 and CYC140 in hematological malignancies and CYC065 in advanced solid... More
